Table 2. Cox Hazards Model Analysis of Variables at Diagnosis for the Occurrence of ESRD during Follow-Up in Patients with MPA and GPA.
| Variables | Univariable | Multivariable (without MMF only) | Multivariable (with MMF only) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | |
| Age (yr) | 0.994 | 0.964, 1.026 | 0.726 | ||||||
| Male sex | 0.727 | 0.258, 2.051 | 0.546 | ||||||
| Body mass index | 0.928 | 0.782, 1.100 | 0.388 | ||||||
| Smoking history | 0.611 | 0.000, 6500.122 | 0.046 | 0.000 | 0.000, 0.000 | 0.984 | 0.000 | 0.000, 0.000 | 0.989 |
| MPO-ANCA (or P-ANCA) positivity | 1.719 | 0.496, 5.956 | 0.393 | ||||||
| PR3-ANCA (or C-ANCA) positivity | 0.819 | 0.187, 3.583 | 0.791 | ||||||
| Renal manifestation | 2.354 | 0.654, 8.471 | 0.190 | ||||||
| BVAS | 1.079 | 1.014, 1.147 | 0.016 | 1.087 | 1.018, 1.161 | 0.012 | 1.172 | 1.068, 1.285 | 0.001 |
| FFS | 1.588 | 0.971, 2.598 | 0.066 | ||||||
| ESR | 1.005 | 0.994, 1.017 | 0.387 | ||||||
| CRP | 1.002 | 0.995, 1.009 | 0.584 | ||||||
| CKD (stage 3–5) | 0.880 | 0.344, 2.254 | 0.790 | ||||||
| DM | 1.569 | 0.606, 4.063 | 0.354 | ||||||
| HTN | 2.728 | 1.060, 7.020 | 0.037 | 3.201 | 1.186, 8.638 | 0.022 | 1.778 | 0.547, 5.778 | 0.338 |
| Dyslipidemia | 1.492 | 0.528, 4.220 | 0.450 | ||||||
| MMF only over AZA only | 1.835 | 1.032, 3.264 | 0.039 | 4.823 | 1.338, 17.384 | 0.016 | |||
ESRD, end-stage renal disease; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; MMF, mycophenolate mofetil; HR, hazard ratio; CI, confidence interval; MPO, myeloperoxidase; ANCA: antineutrophil cytoplasmic antibody; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BVAS, Birmingham vasculitis activity score; FFS, five-factor score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; AZA, azathioprine.